Rasmussen, B, Göhring, G, Bernard, E, Nilsson, L, Tobiasson, M, Jädersten, M, Garelius, H, Dybedal, I, Grønbaek, K, Ejerblad, E, Lorenz, F, Flogegård, M, Marcher, C W, Öster Fernström, A, Cavelier, L, Papaemmanuil, E, Ebeling, F, Kittang, A O, Nørgaard, J M, Saft, L, Möllgård, L & Hellström-Lindberg, E 2022, ' “Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)” ', Leukemia, vol. 36, no. 5, pp. 1436-1439 . https://doi.org/10.1038/s41375-022-01537-w Rasmussen, B, Gohring, G, Bernard, E, Nilsson, L, Tobiasson, M, Jadersten, M, Garelius, H, Dybedal, I, Gronbaek, K, Ejerblad, E, Lorenz, F, Flogegard, M, Marcher, C W, oster Fernstrom, A, Cavelier, L, Papaemmanuil, E, Ebeling, F, Kittang, A O, Norgaard, J M, Saft, L, Mollgard, L & Hellstrom-Lindberg, E 2022, ' "Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)" ', Leukemia, vol. 36, no. 5, pp. 1436-1439 . https://doi.org/10.1038/s41375-022-01537-w